Top Story

Samsung Bioepis, Takeda collaborate on severe pancreatitis therapy

August 21, 2017

Samsung Bioepis has joined with Takeda to develop multiple novel biologic therapies, including the collaboration’s first therapeutic candidate, TAK-671 for severe acute pancreatitis, according to a press release.

“Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in the release. “Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”

Bacteria film location, consistency differs in healthy, cancerous colons

August 18, 2017
As colon cancer rates increase in the U.S., researchers are looking to gut microbiota to find early predictors, such as bacterial biofilms found on the colon mucosa…
Meeting News

Microbiome research ethics looking at a ‘critical gap’

August 18, 2017
With a shift from observational to experimental research using human microbiomes, ethical questions associated with the research and use of microbiomes are on the rise…

FDA clears use of Cellvizio for robotic-assisted surgery

August 16, 2017
Mauna Kea Technologies, inventor of Cellvizio, a multidisciplinary confocal laser endomicroscopy platform, has received FDA 510(k) clearance for its CelioFlex UHD…
More Headlines »

The Transplant Patient with HCV Infection

No commercial support for this activity.

Gastroesophageal reflux is a common chronic condition associated with significant morbidity, resource utilization, and…
More »
GI Bookshelf

Chapter 4: Ear, Nose, and Throat Manifestations of GERD

From Extraesophageal Manifestations of GERD
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

Meeting News Coverage

VIDEO: Positional therapy device reduces nocturnal acid reflux symptoms in pregnant women

November 3, 2015
More »